Department of Clinical Immunology and Rheumatology, King George's Medical University, Lucknow, India.
Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Pensnett Road, Dudley, DY1 2HQ, UK.
Clin Rheumatol. 2022 Dec;41(12):3897-3913. doi: 10.1007/s10067-022-06365-y. Epub 2022 Sep 9.
Outcomes of COrona VIrus Disease-19 (COVID-19) in patients with rheumatic diseases (RDs) reported in various studies are heterogenous owing to the influence of age and comorbidities which have a significant bearing on the infection risk, severity, morbidity, and mortality. Diabetes mellitus (DM) and RDs are closely linked with underlying pathobiology and treatment of RDs affecting the risk for DM as well as the glycemic control. Hence, we undertook this narrative review to study the influence of DM on outcomes of COVID-19 in patients with RDs. Additionally, aspects of patient attitudes and immune response to COVID-19 vaccination were also studied. The databases of MEDLINE/PubMed, Scopus, and Directory of Open Access Journals (DOAJ) were searched for relevant articles. Studies from mixed cohorts revealed insufficient data to comment on the influence of DM on the risk of infection, while most studies showed twice the odds for hospitalization and mortality with DM. Specific cohorts of rheumatoid arthritis and systemic lupus erythematosus revealed a similar association. Poor health was noted in patients with spondyloarthritis and DM during the pandemic. The presence of DM did not affect patient attitudes towards vaccination and did not predispose to additional vaccine-related adverse effects. Immune response to inactivated vaccines was reduced but mRNA vaccines were maintained in patients with DM. Detailed assessment of DM with its duration, end-organ damage, and glycemic control along with a focused association of DM with various aspects of COVID-19 like risk, hospitalization, severity, mortality, post-COVID sequelae, immune response to infection, and vaccination are needed in the future. Key Points • Diabetes mellitus is associated with the severity of infection, COVID-19-related hospitalization, and mortality in rheumatic diseases across most studies but studies analyzing its specific role are lacking. • Poor outcomes of COVID-19 in RA and poor health in spondyloarthritis are strongly associated with diabetes mellitus. • Diabetes mellitus may negatively influence the humoral response to inactivated vaccines but does not seem to affect the immune responses to mRNA vaccines. • Diabetes mellitus does not influence the attitude towards vaccination or deviation from the prescribed medications during the pandemic.
在各种研究中,报告的患有风湿性疾病(RDs)的 COrona VIrus Disease-19(COVID-19)患者的结局是不同的,这是由于年龄和合并症的影响,这些因素对感染风险、严重程度、发病率和死亡率有重大影响。糖尿病(DM)和 RDs 与潜在的病理生物学密切相关,治疗 RDs 会影响 DM 的风险以及血糖控制。因此,我们进行了这项叙述性综述,以研究 DM 对患有 RDs 的 COVID-19 患者结局的影响。此外,还研究了患者对 COVID-19 疫苗接种的态度和免疫反应的各个方面。搜索了 MEDLINE/PubMed、Scopus 和开放获取期刊目录(DOAJ)数据库中的相关文章。混合队列的研究提供的数据不足以说明 DM 对感染风险的影响,而大多数研究表明,DM 患者住院和死亡的风险增加了一倍。类风湿关节炎和系统性红斑狼疮的特定队列也显示出类似的关联。在大流行期间,患有脊柱关节炎和 DM 的患者健康状况不佳。DM 患者的态度并不影响他们对疫苗接种的态度,也不会导致更多与疫苗相关的不良反应。DM 患者对灭活疫苗的免疫反应降低,但对 mRNA 疫苗的免疫反应保持不变。未来需要详细评估 DM 及其持续时间、终末器官损伤和血糖控制,并重点研究 DM 与 COVID-19 的各个方面的关联,如风险、住院、严重程度、死亡率、COVID-19 后后遗症、感染和疫苗接种的免疫反应。 关键点 • 在大多数研究中,糖尿病与风湿性疾病的感染严重程度、COVID-19 相关住院和死亡率相关,但缺乏分析其具体作用的研究。 • 类风湿关节炎中 COVID-19 的不良结局和脊柱关节炎中的健康状况不佳与糖尿病密切相关。 • 糖尿病可能会对灭活疫苗的体液反应产生负面影响,但似乎不会影响对 mRNA 疫苗的免疫反应。 • 糖尿病不会影响大流行期间对疫苗接种的态度或偏离规定的药物治疗。